Screening for the potential of a drug candidate to cause idiosyncratic drug reactions

Drug Discovery Today

Volumn 8, Issue 18, 2003, Pages 832-837

  Uetrecht, Jack ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cytotoxicity; Drug Discovery; IDRs; Markers; Pharmaceutical Science; Pharmacology; Reactive metabolites; Screening; Techniques Methods; Toxicology

Indexed keywords

FELBAMATE; GLUTATHIONE; LAMOTRIGINE; QUINONE DERIVATIVE; TROGLITAZONE;

APLASTIC ANEMIA; COVALENT BOND; DOSE RESPONSE; DRUG SCREENING; GLUTATHIONE METABOLISM; HEPATITIS; HUMAN; NONHUMAN; OXIDATIVE STRESS; QT INTERVAL; RASH; REVIEW; RISK FACTOR; TOXICITY TESTING;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; PREDICTIVE VALUE OF TESTS;

EID: 0042831348     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02816-2     Document Type: Review

References (31)

1. Lasser K.E., et al. Timing of new Black Box Warnings and withdrawals for prescription medications. J. Am. Med. Assoc. 287:2002;2215-2220.
2. Cavero I., et al. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin. Pharmacother. 1:2000;947-973.
3. Naisbitt D.J., et al. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf. 23:2000;483-507.
4. Scheen A.J. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf. 24:2001;873-888.
5. Dieckhaus C.M., et al. Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem. Biol. Interact. 142:2002;99-117.
6. Messenheimer J., et al. Safety review of adult clinical trial experience with lamotrigine. Drug Saf. 18:1998;281-296.
7. Baillie T.A., et al. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182:2002;188-196.
8. Pohl L.R., et al. The immunologic and metabolic basis of drug hypersensitivities. Annu. Rev. Pharmacol. 28:1988;367-387.
9. Park B.K., et al. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem. Res. Toxicol. 11:1998;969-988.
10. Griem P., et al. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol. Today. 19:1998;133-141.
11. Medzhitov R., Janeway C.A. Jr. Innate immune recognition and control of adaptive immune responses. Semin. Immunol. 10:1998;351-353.
12. Matzinger P. An innate sense of danger. Semin. Immunol. 10:1998;399-415.
13. Matzinger P. Tolerance, danger and the extended family. Annu. Rev. Immunol. 12:1994;991-1045.
14. Uetrecht J.P. New concepts in immunology relevant to idiosyncratic drug reactions: the 'danger hypothesis' and innate immune system. Chem. Res. Toxicol. 12:1999;387-395.
15. Pirmohamed M., et al. The danger hypothesis-potential role in idiosyncratic drug reactions. Toxicology. 181-182:2002;55-63.
16. Byrd R.B., et al. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. J. Am. Med. Assoc. 241:1979;1239-1241.
17. Smith M.T. Mechanisms of troglitazone hepatotoxicity. Chem. Res. Toxicol. 16:2003;679-687.
18. Pichler W.J. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr. Opin. Allergy Clin. Immunol. 2:2002;301-305.
19. Uetrecht, J. Bioactivation. In Cytochrome P450 and Drug Metabolism (Obach, R.S. et al., eds), Fontis Media (in press).
20. Monks T.J., Jones D.C. The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers. Curr. Drug Metab. 3:2002;425-438.
21. Uetrecht J. N-oxidation of drugs associated with idiosyncratic drug reactions. Drug Metab. Rev. 34:2002;651-665.
22. Li C., et al. Studies on the chemical reactivity of 2-phenylpropionic acid 1-O-acyl glucuronide and S-acyl-CoA thioester metabolites. Chem. Res. Toxicol. 15:2002;1309-1317.
23. Boelsterli U.A. Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr. Drug Metab. 3:2002;439-450.
24. Ju C., Uetrecht J.P. Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J. Pharmacol. Exp. Ther. 288:1999;51-56.
25. Baillie T.A., Davis M.R. Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 22:1993;319-325.
26. Uetrecht J.P., et al. Metabolism of vesnarinone by activated neutrophils; implications for vesnarinone-induced agranulocytosis. J. Pharmacol. Exp. Ther. 270:1994;865-872.
27. Reilly T.P., et al. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J. Invest. Dermatol. 114:2000;1164-1173.
28. Baillie, T.A. Chemically reactive metabolites in drug discovery and development. In Cytochrome P450 and Drug Metabolism (Obach, R.S. et al., eds), Fontis Media (in press).
29. Shenton, J.M. et al. Characterization of a Potential Animal Model of an Idiosyncratic Drug Reaction: Nevirapine-Induced Skin Rash in the Rat. Chem. Res. Toxicol. (in press).
30. Ju C., Uetrecht J.P. Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. Curr. Drug Metab. 3:2002;367-377.
31. Mallal S., et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 359:2002;727-732.